NasdaqCM:WHWKBiotechs
Whitehawk Therapeutics (WHWK) Swings To US$0.37 EPS Profit Challenging Bearish Turnaround Skepticism
Whitehawk Therapeutics (WHWK) has opened FY 2025 with first half revenue of US$7.1 million and Basic EPS of US$0.37, following a FY 2024 second half that saw revenue of US$14.5 million and a loss per share of US$1.14. Over the past year, the company has moved from Basic EPS of a US$2.36 loss on US$26.0 million of trailing twelve month revenue to a US$0.33 loss on US$7.1 million of trailing twelve month revenue, giving investors a clearer read on how its earnings profile and margins are...